United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum
UTHR(NASDAQ:UTHR) SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer, will provide an overview and update on the company during a fireside chat session at the Bernstein 2nd Annual Healthcare Forum in New York. The session will take place on Tuesday, September 23, 2025, from 1:10 p.m. to 1:50 p.m., Eastern Standard Time, and can be ac
United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
UTHR(NASDAQ:UTHR) SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity (FVC) relative to placebo. Tyvaso demonstrated superiority over placebo for the chang
United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
UTHR(NASDAQ:UTHR) SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s operations during a fireside chat session at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The session will take place on Monday, September 8, 2025, from 3:20 p.m. to 3:55 p.m., Eastern Standard Ti
B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $315
UTHRForecasting The Future: 7 Analyst Projections For United Therapeutics
UTHRCantor Fitzgerald Initiates Coverage On United Therapeutics with Overweight Rating, Announces Price Target of $405
UTHRHC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $425 Price Target
UTHRJP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $350
UTHRMorgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $348
UTHRUnited Therapeutics Q1 EPS $6.63 Beats $6.52 Estimate, Sales $794.40M Beat $729.83M Estimate
UTHRDemystifying United Therapeutics: Insights From 4 Analyst Reviews
UTHRWells Fargo Downgrades United Therapeutics to Equal-Weight, Lowers Price Target to $314
UTHRJP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $355
UTHRB of A Securities Upgrades United Therapeutics to Neutral, Maintains Price Target to $314
UTHRUnited Therapeutics Announces Series Of Presentations And Sponsored Events At ATS 2025, Highlighting Pulmonary Hypertension And Fibrosis Studies
UTHRUnited Therapeutics Corporation Says It Will Feature Clinical Data Across Its Commercial And Development Portfolio At International Society For Heart And Lung Transplantation 45th Annual Meeting And Scientific Sessions
UTHRUnited Therapeutics Q4 2024 GAAP EPS $6.19 Misses $6.27 Estimate, Sales $735.90M Beat $734.74M Estimate
UTHRGoldman Sachs Maintains Neutral on United Therapeutics, Raises Price Target to $302
UTHROppenheimer Maintains Outperform on United Therapeutics, Raises Price Target to $600
UTHRArgus Research Maintains Buy on United Therapeutics, Raises Price Target to $400
UTHRHC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $425
UTHRExpert Ratings For United Therapeutics
UTHRJP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $300
UTHRRecap: United Therapeutics Q1 Earnings
UTHRUnited Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
United Therapeutics Q1 EPS $5.03 Beats $3.34 Estimate, Sales $461.90M Beat $420.02M Estimate
UTHREarnings Outlook For United Therapeutics
UTHRUnited Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement.
Analysts estimate that United Therapeutics will report an earnings per share (EPS) of $3.34.
United Therapeutics Q1 2022 Earnings Conference Call On May 4, 2022 At 09:00 AM ET
UTHRUnited Therapeutics (NASDAQ:UTHR) will host a conference call at 09:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
How to Attend United Therapeutics (UTHR) Conference Call
Follow this link to access the live webcast.
